AP2004003050A0 - Chemically modified human growth hormone conjugates - Google Patents

Chemically modified human growth hormone conjugates

Info

Publication number
AP2004003050A0
AP2004003050A0 APAP/P/2004/003050A AP2004003050A AP2004003050A0 AP 2004003050 A0 AP2004003050 A0 AP 2004003050A0 AP 2004003050 A AP2004003050 A AP 2004003050A AP 2004003050 A0 AP2004003050 A0 AP 2004003050A0
Authority
AP
ARIPO
Prior art keywords
chemically modified
growth hormone
human growth
modified human
hgh
Prior art date
Application number
APAP/P/2004/003050A
Inventor
Rory F Finn
Wei Liao
Ned R Siegel
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AP2004003050A0 publication Critical patent/AP2004003050A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

The present invention provides a chemically modified human Growth Hormone (hGH) prepared by binding a water soluble polymer to the protein the chemically modified protein according to the present invention may have a much longer lasting (hGH) activity than that of the unmodified hGH enabling reduced dose and scheduling opportunities
APAP/P/2004/003050A 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates AP2004003050A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
AP2004003050A0 true AP2004003050A0 (en) 2004-06-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003050A AP2004003050A0 (en) 2001-11-20 2002-11-20 Chemically modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003061577A2 (en) * 2002-01-18 2003-07-31 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compound
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
CA2498167C (en) 2002-09-09 2012-03-20 Nektar Therapeutics Al, Corporation Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
EP1673464A2 (en) * 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
BRPI0506864A (en) * 2004-01-21 2007-05-29 Novo Nordisk As method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease
CN101010105A (en) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
WO2006073846A2 (en) * 2004-12-22 2006-07-13 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (en) 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
MX2007012887A (en) 2005-04-18 2007-12-10 Novo Nordisk As Il-21 variants.
BRPI0615351A2 (en) * 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag liquid formulations of pegylated growth hormone
CN104710503B (en) * 2005-11-08 2023-04-25 Ambrx 公司 Promoters for modification of unnatural amino acids and unnatural amino acid polypeptides
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
WO2008049920A2 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
PL2272875T3 (en) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
BRPI0911722B1 (en) * 2008-07-31 2022-09-13 Pharmaessentia Corp PEPTIDE-POLYMER CONJUGATE
BRPI0917000A2 (en) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag protein conjugates with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
WO2010030366A2 (en) * 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
CN105963710A (en) 2009-08-06 2016-09-28 诺沃—诺迪斯克保健股份有限公司 Growth hormones with prolonged in-vivo efficacy
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
PL2525834T3 (en) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
WO2011146518A2 (en) * 2010-05-17 2011-11-24 Cebix Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
ES2841123T3 (en) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Growth hormone compound formulation
JP6820841B2 (en) 2014-11-06 2021-01-27 ファーマエッセンティア コーポレイション Dosing regimen for pegged interferon
KR20170125839A (en) * 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Conjugates of an il-7 moiety and an polymer
SG11201802180TA (en) * 2015-09-18 2018-04-27 Univ Miyazaki Long-acting adrenomedullin derivative
CN114539384A (en) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, and preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (en) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilization of somatotropin through modification of cysteine residues
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5849535A (en) * 1995-09-21 1998-12-15 Genentech, Inc. Human growth hormone variants
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
BR0008759B1 (en) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Methods for the production of protein containing free cysteine residues
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
EP1352062A2 (en) * 2001-01-11 2003-10-15 Maxygen Aps Improved growth hormone molecules

Also Published As

Publication number Publication date
PL374354A1 (en) 2005-10-17
CO5580794A2 (en) 2005-11-30
JP2006321808A (en) 2006-11-30
CA2467731A1 (en) 2003-05-30
EA200400565A1 (en) 2005-06-30
ECSP045114A (en) 2004-07-23
AU2002356990A1 (en) 2003-06-10
MA27544A1 (en) 2005-10-03
GEP20063860B (en) 2006-06-26
EA008505B1 (en) 2007-06-29
OA13063A (en) 2006-11-10
EP1453859A2 (en) 2004-09-08
EA200700431A1 (en) 2008-02-28
BR0214451A (en) 2006-05-30
WO2003044056A2 (en) 2003-05-30
HRP20040448A2 (en) 2006-02-28
MXPA04004809A (en) 2004-08-11
ZA200403907B (en) 2007-12-27
IS7268A (en) 2004-05-17
WO2003044056A3 (en) 2003-08-21
IL162031A0 (en) 2005-11-20
RS53104A (en) 2006-10-27
CN1608079A (en) 2005-04-20
KR20070072924A (en) 2007-07-06
KR20050044858A (en) 2005-05-13
TNSN04090A1 (en) 2006-06-01
HUP0500997A2 (en) 2007-11-28
NO20042182L (en) 2004-08-11
JP2005525302A (en) 2005-08-25

Similar Documents

Publication Publication Date Title
AP2004003050A0 (en) Chemically modified human growth hormone conjugates
MXPA05004993A (en) Chemically-modified human growth hormone conjugates.
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
MX344559B (en) Pegylated recombinant human growth hormone compounds.
CA2594561C (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
TW200621291A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
BG104070A (en) Chimeric protein of interleukin-6, soluble receptor/ligand, its analogues and their application
YU101503A (en) A novel engineered superantigen for human therapy
NL300830I1 (en) Protein Q, a recombinant chimeric protein, consisting of five antigenic fragments of four different Leishmania infantum (zymodeme Mon-1) proteins
AU4011300A (en) Compositions and methods for the treatment of immune related diseases
TNSN04235A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
MXPA04000068A (en) Chemically-modified progenipoietin conjugates.
MXPA04001986A (en) Compositions and methods for the treatment of immune related diseases.
HUP0402334A2 (en) Modified human growth hormone
WO2002099438A3 (en) Modulation of steroid hormone uptake
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
DE60207257D1 (en) HETEROCARPIN, A PROTEIN BINDING HUMANES GHRH
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2007005995A3 (en) Compositions for buccal delivery of human growth hormone
WO2002102849A3 (en) Bcmp-101, a cancer associated protein